Results 21 to 30 of about 2,198,265 (159)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage

ESC Heart Failure, 2020
Aims Cardiac transthyretin amyloidosis (ATTR‐CM) is a progressive and fatal condition. Prognosis can be determined at diagnosis according to the National Amyloidosis Centre (NAC) transthyretin amyloidosis (ATTR) stage.
Steven Law, Aviva Petrie, Liza Chacko, Oliver C. Cohen, Sriram Ravichandran, Janet A. Gilbertson, Dorota Rowczenio, Ashutosh Wechalekar, Ana Martinez‐Naharro, Helen J. Lachmann, Carol J. Whelan, David F. Hutt, Philip N. Hawkins, Marianna Fontana, Julian D. Gillmore   +14 more
doaj   +1 more source

Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study

Orphanet Journal of Rare Diseases, 2023
Background Transthyretin cardiac cardiomyopathy (ATTR-CM) is a rare but life-threatening disease. Tafamidis is an effective treatment for patients with ATTR-CM, however its long-term effects on cardiac remodeling and cardiac amyloid deposition are ...
Cheng-Hsuan Tsai, Chi-Chao Chao, Sung-Tsang Hsieh, An-Li Yu, Yuan-Kun (Aden) Wu, Mei-Fang Cheng, Ming-Jen Lee, Chia-Hung Chou, Chia-Tung Shun, Hsueh-Wen Hsueh, Jimmy Jyh-Ming Juang, Ping-Huei Tseng, Mao-Yuan Su, Yen-Hung Lin   +13 more
doaj   +1 more source

Navigating the emerging landscape of asymptomatic ATTR-CM: challenges, opportunities and the path ahead. [PDF]

Future Cardiol
Transthyretin amyloid cardiomyopathy (ATTR-CM) has long been considered a rare and inexorably fatal condition. However, advances in noninvasive diagnosis, disease awareness, and available treatments have enabled diagnosis in asymptomatic stages, before ...
Porcari A.
europepmc   +2 more sources

The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary. [PDF]

Future Cardiol
[Abstract] What is this summary about?: This summary explains some results of a study called ATTR-ACT and its ongoing long-term extension study that were published in the European Journal of Heart Failure.
Grogan M, Davis MK, Crespo Leiro MG, Sultan MB, Gundapaneni B, Angeli FS, Hanna M.   +6 more
europepmc   +2 more sources

Race, Sex, and Ejection Fraction-Based Differences in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Risk Prediction. [PDF]

J Clin Med
Background: The early detection of transthyretin cardiac amyloidosis (ATTR-CM) is essential, with Tc-99m pyrophosphate scintigraphy (PYP scan) being a key diagnostic tool.
Chedid El Helou M, Gupta M, Hussain M, Hanna M, Blumer V, William P, Desai MY, Abadie BQ, Ives L, Tang WHW, Jaber WA, Collier P, Martyn T.   +12 more
europepmc   +2 more sources

Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an important cause of heart failure in older individuals. Misfolding and deposition of transthyretin or prealbumin protein causes ATTR‐CM in the context of a normal (wild‐type) or variant TTR ...
Frederick L. Ruberg, William S. Blaner, Codruta Chiuzan, Lawreen H. Connors, Andrew J. Einstein, Denise Fine, Stephen Helmke, Damian Kurian, Shivda Pandey, Farbod Raiszadeh, Carlos Rodriguez, Natalia Sabogal, Sergio Teruya, Morgan Winburn, Wendy K. Chung, Elizabeth Cohn, Edward J. Miller, Jeffery W. Kelly, Mathew S. Maurer   +18 more
doaj   +1 more source

Progress in RNA-targeting and Gene Editing Therapies for Transthyretin Amyloidosis Cardiomyopathy

罕见病研究, 2023
Transthyretin(TTR) protein is a tetramer protein, synthesized mainly by the liver. TTR can be misfolded and deposited as amyloid fibrilae and deposited in the myocardial interstroma leading to transthyroxin amyloidosis cardiomyopathy (ATTR-CM).
NIU Ziran, HU Yang, LIU Qingyang, MA Yuanyuan, LIU Jianing, LIU Xin, ZHANG Bo   +6 more
doaj   +1 more source

Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR-CM. [PDF]

ESC Heart Fail
Publisher Copyright: © 2025 Pfizer Inc and The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.Aims: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience delayed ...
Garcia-Pavia P, Del Moral FJH, Cappelli F, Piriou N, Barriales-Villa R, Munteanu C, Bahus C, Keohane D, Mallaina P, Itti E, Damy T, Elliott P.   +11 more
europepmc   +2 more sources

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries

ESC Heart Failure, 2022
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan.
Rosa Lauppe, Johan Liseth Hansen, Anna Fornwall, Katarina Johansson, Mark H. Rozenbaum, Anne Mette Strand, Merja Väkeväinen, Johanna Kuusisto, Einar Gude, J. Gustav Smith, Finn Gustafsson   +10 more
doaj   +1 more source

Effect of Timely Availability of TTR-Stabilizing Therapy on Diagnosis, Therapy, and Clinical Outcomes in ATTR-CM. [PDF]

J Clin Med
Background: Tafamidis reduces cardiovascular morbidity and mortality in transthyretin amyloid cardiomyopathy (ATTR-CM), yet availability and access to therapy vary. Objective: To determine how availability and access to tafamidis impact time-to-diagnosis,
Dobner S, Zarro S, Wieser F, Kassar M, Alaour B, Wiedemann S, Bakula A, Caobelli F, Stortecky S, Gräni C, Hunziker L, Bernhard B.   +11 more
europepmc   +2 more sources